BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial

BriaCell Therapeutics Corp BCTX has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies.
Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in BriaCell's ongoing Phase 1/2a study with Incyte Corporation INCY in metastatic or locally recurrent breast cancer patients.
Specifically, ImaginAb will receive license fees and payments to support the implementation of its CD8 ImmunoPET technology. No other terms are disclosed.
The CD8 ImmunoPET technology allows whole-body visualization of increased CD8 T cells, especially those infiltrating and attacking tumors.
Price Action: BCTX shares are down 2.02% at $5.59 during the market session on the last check Thursday.